June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As

First Page		Document Content
Oncology Orphan drugs Myelodysplastic syndrome Syndromes Azacitidine Decitabine Cyclacel Medicine Nucleosides Triazines		June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 24,02 KB Share Document on Facebook

	BECOMING AN EMPOWERED PATIENT: A Toolkit for the Undiagnosed Global Genes SWAN (Syndromes Without DocID: 1vceu - View Document
	MANAGEMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES Nicolas Bonadies Department of Haematology and Central Haematology Laboratory, Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland Co DocID: 1uHHh - View Document
	Larva Migrans Overview Last Updated: December 2013 Larva migrans is a group of clinical syndromes that result from the movement of parasite larvae through host tissues. The symptoms vary with the location and extent DocID: 1uzK6 - View Document
	Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes DocID: 1uiD5 - View Document
	duplications are called, actually causing autism and the other syndromes? A “eureka!” moment for autism research One way to find out would be to check whether clipping out the mouse equivalent of human 16p11.2 or add DocID: 1tri5 - View Document